Cargando…

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease

BACKGROUND: The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the treatment of non‐small cell lung cancer (NSCLC) in clinical practice; however, in patients with preexis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanai, Osamu, Kim, Young Hak, Demura, Yoshiki, Kanai, Makiko, Ito, Tsuyoshi, Fujita, Kohei, Yoshida, Hironori, Akai, Masaya, Mio, Tadashi, Hirai, Toyohiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026605/ https://www.ncbi.nlm.nih.gov/pubmed/29782069 http://dx.doi.org/10.1111/1759-7714.12759

Ejemplares similares

Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017)

Decreased handgrip strength can predict lung function impairment in male workers: a cross sectional study
por: Kanai, Makiko, et al.
Publicado: (2020)

Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
por: Imakita, Takuma, et al.
Publicado: (2022)

Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
por: Kanai, Osamu, et al.
Publicado: (2017)

Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer
por: Nakashima, Koki, et al.
Publicado: (2021)

Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density
por: Fujita, Kohei, et al.
Publicado: (2018)

Impact of COVID‐19 pandemic on lung cancer treatment scheduling
por: Fujita, Kohei, et al.
Publicado: (2020)

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
por: Imakita, Takuma, et al.
Publicado: (2023)

Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
por: Uchida, Naohiro, et al.
Publicado: (2017)

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
por: Funazo, Tomoko Yamamoto, et al.
Publicado: (2019)

Utility of Endoscopic Ultrasound with Bronchoscope-guided Fine-needle Aspiration for Detecting Driver Oncogenes in Non-small-cell Lung Cancer during Emergency Situations: Case Series
por: Nakashima, Koki, et al.
Publicado: (2020)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival
por: Nakashima, Koki, et al.
Publicado: (2020)

Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation
por: Fujita, Kohei, et al.
Publicado: (2021)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021)

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy
por: Ito, Takanori, et al.
Publicado: (2023)

Simultaneous regression of non‐small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer
por: Oi, Issei, et al.
Publicado: (2023)

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
por: Nomizo, Takashi, et al.
Publicado: (2017)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Comparison of frailty in patients with nontuberculous mycobacterial lung disease and bronchiectasis: a prospective cohort study
por: Fujita, Kohei, et al.
Publicado: (2022)

Afebrile tension pyopneumothorax due to anaerobic bacteria: Fistula or gas production?
por: Kanai, Osamu, et al.
Publicado: (2021)

No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
por: Kanai, Osamu, et al.
Publicado: (2021)

Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient
por: Fujita, Kohei, et al.
Publicado: (2022)

2632. Duration of viable SARS-CoV-2 shedding in immunocompromised COVID-19 patients during the widespread vaccination era
por: Kanai, Osamu, et al.
Publicado: (2023)

525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease
por: Fujita, Tetsuo, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
por: Ogimoto, Tatsuya, et al.
Publicado: (2023)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

A 92‐year‐old patient with thoracic empyema successfully treated by CT‐guided insertion of a pigtail catheter
por: Fujita, Kohei, et al.
Publicado: (2023)

Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
por: Nakashima, Koki, et al.
Publicado: (2020)

The Association between Malignant Pleural Mesothelioma and Thoracic Radiation Therapy for Hodgkin's Lymphoma: The First Case Report in Japan
por: Nakashima, Koki, et al.
Publicado: (2020)

Nivolumab‐induced severe acute kidney injury with a long latent phase in a patient with non‐small‐cell lung cancer: A case report
por: Uchida, Naohiro, et al.
Publicado: (2018)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

MORTALITY AND ITS PREDICTORS IN PATIENTS WITH COVID-19 WITH PREEXISTING INTERSTITIAL LUNG DISEASE
por: DUTT, N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02rjk8rr7upmb5ur55p152r65o